No annual revenue total was found in Hemab Therapeutics Holdings, Inc.'s SEC filings.
Hemab Therapeutics Holdings, Inc. (COAG) files with the SEC under industry code 2836, Biological Products, (No Diagnostic Substances). As of Jun 30, 2026 it held $457.5 million in cash and investments and $1.0 million in total debt.
Revenue
—
Net income
—
Operating cash flow
—
Free cash flow
—
EPS
—
Dividend per share
None
Shares outstanding
—
Net cash
$456.43M
as of Jun 30, 2026
Operating margin
—
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- COAG (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Cambridge, MA
- SEC filer status
- , Emerging growth company
- SEC CIK
- 2114044
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Officer or director change
|
Sep 24, 2026 | Sep 24, 2026 |
| 10-Q | Quarterly report | Aug 11, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 11, 2026 | Aug 11, 2026 |
| 10-Q | Quarterly report | May 21, 2026 | Mar 31, 2026 |
| 8-K |
Current report
Results of operations
|
May 21, 2026 | May 21, 2026 |
| 8-K |
Current report
Officer or director change
|
May 11, 2026 | May 8, 2026 |
All 50 Hemab Therapeutics Holdings, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.